A phase 1/2 study of the TORC1/2 inhibitor onatasertib combined with toripalimab in patients with advanced solid tumors: Cervical cancer cohort

被引：0
|
作者：
Yuan, Li
Shu, Pei
Li, Xiaoyu
Li, Guiling
Zhang, Keqiang
Lai, Lin
Hong, Jinsheng
Huang, Chu-Ying
Wang, Yongsheng
Xie, Hui
Zheng, Li
Zhou, Qi
机构：
[1] Chongqing Univ Canc Hosp, Chongqing, Peoples R China
[2] Sichuan Univ, West China Hosp, Natl Med Prod Adm Key Lab Clin Res & Evaluat Inno, Clin Trial Ctr,State Key Lab Biotherapy, Chengdu, Peoples R China
[3] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China
[4] Hunan Canc Hosp, Changsha, Peoples R China
[5] Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Dept Abdominal Oncol, Enshi, Peoples R China
[6] Fujian Med Univ, Dept Radiotherapy, Ctr Canc, Affiliated Hosp 1, Fuzhou, Peoples R China
[7] Hubei Selenium & Human Hlth Inst, Cent Hosp Enshi Tujia & Miao Autonomous Prefectur, Enshi, Peoples R China
[8] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[9] Antengene Corp, Dept Clin Res & Dev, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5509
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors
    de Braud, Filippo
    Machiels, Jean-Pascal H.
    Boggiani, Daniela
    Rottey, Sylvie W. H.
    Duca, Matteo
    Laruelle, Marie
    Salvagni, Stefania
    Damian, Silvia
    Lapeire, Lore D. F.
    Tiseo, Marcello
    Dermine, Alexandre
    Ould-Kaci, Mahmoud
    Braunger, Juergen
    Rascher, Juliane
    Fischer, Daniela
    Hoefler, Josef
    Mariani, Gabriella L.
    Cresta, Sara
    CANCERS, 2020, 12 (06)
  • [32] A retrospective study of toripalimab combined with concurrent chemoradiotherapy in patients with recurrent/advanced cervical cancer
    Song, Y.
    Song, Y.
    Wang, C.
    Li, X.
    Li, Y.
    Zhang, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S755 - S755
  • [33] Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
    Matthew R Janes
    Jose J Limon
    Lomon So
    Jing Chen
    Raymond J Lim
    Melissa A Chavez
    Collin Vu
    Michael B Lilly
    Sharmila Mallya
    S Tiong Ong
    Marina Konopleva
    Michael B Martin
    Pingda Ren
    Yi Liu
    Christian Rommel
    David A Fruman
    Nature Medicine, 2010, 16 : 205 - 213
  • [34] A Phase Ib study of Wee1 inhibitor adavosertib in patients with advanced solid tumors
    Falchook, Gerald S.
    Sachdev, Jasgit
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh
    Chmielecki, Juliann
    Jones, Suzanne
    Spigel, David R.
    Johnson, Melissa
    CANCER RESEARCH, 2019, 79 (13)
  • [35] Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)
    Qin, Shukui
    Lin, Xiaoyan
    Meng, Zhiqaing
    Ren, Zhenggang
    Bai, Yuxian
    Gu, Shanzhi
    Zheng, Li
    Li, Qiu
    Oh, Sun-Yong
    Guo, Yabing
    Kang, Yoong-Koo
    Kao, Wei-Yu
    Li, Wei
    Yoon, Jung-Hwan
    Zhang, Helong
    Chen, Pei-Jer
    Yang, Tsai-Sheng
    Heo, Jeong
    Zheng, Zhendong
    Xie, Hui
    Yu, Zhinuan
    CANCER RESEARCH, 2023, 83 (08)
  • [36] TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
    Burris, Howard A., III
    Kurkjian, C. D.
    Hart, L.
    Pant, S.
    Murphy, P. B.
    Jones, S. F.
    Neuwirth, R.
    Patel, C. G.
    Zohren, F.
    Infante, J. R.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (02) : 261 - 273
  • [37] ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer
    Kamath, Suneel
    Tai, David
    Moreno, Irene
    Babiker, Hani
    Jin, Zhaohui
    Yoo, Changhoon
    Ricard, Fabien
    Jen, Kai Yu
    Coward, Jim
    Liu, Jia
    Opdam, Frans
    Millward, Michael
    Ponz-Sarvise, Mariano
    Yachnin, Jeffrey
    Kim, Richard
    Park, Joon Oh
    Subbiah, Vivek
    Schram, Alison M.
    CANCER RESEARCH, 2023, 83 (05)
  • [38] Development of a Practical Synthesis of a TORC1/2 Inhibitor: A Scalable Application of Memory of Chirality
    Hicks, Frederick
    Hou, Yongquan
    Langston, Marianne
    McCarron, Ashley
    O'Brien, Erin
    Ito, Tatsuya
    Ma, Chunrong
    Matthews, Chris
    O'Bryan, Colin
    Provencal, David
    Zhao, Yuxin
    Huang, Jie
    Yang, Qiang
    Li Heyang
    Johnson, Matthew
    Yan Sitang
    Liu Yuqiang
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2013, 17 (05) : 829 - 837
  • [39] Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor
    Janes, Matthew R.
    Limon, Jose J.
    So, Lomon
    Chen, Jing
    Lim, Raymond J.
    Chavez, Melissa A.
    Vu, Collin
    Lilly, Michael B.
    Mallya, Sharmila
    Ong, S. Tiong
    Konopleva, Marina
    Martin, Michael B.
    Ren, Pingda
    Liu, Yi
    Rommel, Christian
    Fruman, David A.
    NATURE MEDICINE, 2010, 16 (02) : 205 - U115
  • [40] TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies
    Howard A. Burris
    C. D. Kurkjian
    L. Hart
    S. Pant
    P. B. Murphy
    S. F. Jones
    R. Neuwirth
    C. G. Patel
    F. Zohren
    J. R. Infante
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 261 - 273
12345